clinical trial · NCT02620163
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Hypertensiontelmisartan/amlodipine 40/5mgYH22162 40/5/12.5 mgtelmisartan/amlodipine 80/5mgYH22162 80/5/25 mgtelmisartan/amlodipine 40/5mg placeboYH22162 40/5/12.5 mg placebotelmisartan/amlodipine 80/5mg placeboYH22162 80/5/25 mg placebo
brief summary
To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment
started
Dec 1, 2015
primary completion
Dec 1, 2016
completion
Dec 1, 2016
last updated
Nov 12, 2024
official title
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol